GH1 and Insulin resistance: Accordingly, genetic variants that primarily reduce GH secretion and signaling would lead to reduced IGF-1 bioactivity but without the consequent effects of elevated GH on fatty acid metabolism and insulin resistance and, hence, no alteration in T2D risk.